Table 2.

Pharmacodynamic parameters based on anti-Xa measurements^* after subcutaneous administration in 20 healthy volunteers

	Average MW	Mna	Dose	t½	Renal clearance	Total clearanceb
	(Da)	(Da)	(IU)	(h)	(% of dose)	(mL/min)
Enoxaparin	4,400	3,100	2,000	3.95 ± 0.65	6.4 ± 6.5	16.67 ± 5.50
			4,000	4.37 ± 0.47	8.7 ± 3.4	13.83 ± 3.17
Nadroparin	4,400	3,700	3,075	3.74 ± 0.68	3.9 ± 1.8	21.50 ± 7.00
Dalteparin	5,700	4,750	2,500	2.81 ± 0.84	3.4 ± 1.5	33.33 ± 11.83

^aNumber average MW; ^bCl/F.

^*Clinical data were extracted from Collignon et al [36] and compiled specifically for this review (MW data from Schroeder et al [31]).